Clinical Trials for Mesothelioma Patients—A Study of Decitabine and FR901228: Prior Concurrent Therapy

Read about the prior concurrent therapy for a current clinical trial about the use of Decitabine and FR901228 for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Prior Concurrent Therapy:
Biologic therapy:
At least 30 days since prior anticancer biologic therapy
Chemotherapy:
At least 30 days since prior anticancer chemotherapy
Prior decitabine or FR901228 (depsipeptide) allowed provided no dose-limiting toxicity was experienced at the scheduled dose
Endocrine therapy:
See Disease Characteristics
Radiotherapy:
See Disease Characteristics
At least 14 days since prior localized radiotherapy to non-target lesions and recovered
At least 30 days since prior anticancer radiotherapy
Surgery:
See Disease Characteristics

Other:
No more than 2 prior systemic cytotoxic treatment regimens
At least a 5 half-life washout period since and no concurrent medication causing corrected QT interval (QTc) prolongation
No concurrent medication causing corrected QTc prolongation
No concurrent anticonvulsants
No concurrent hydrochlorothiazide diuretics
No concurrent digitalis

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.